|
gptkbp:instanceOf
|
gptkb:drug
triptan
|
|
gptkbp:approvalYear
|
1992
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N02CC01
|
|
gptkbp:bioavailability
|
15% (oral)
|
|
gptkbp:brand
|
gptkb:Imigran
Imitrex
|
|
gptkbp:CASNumber
|
103628-46-2
|
|
gptkbp:category
|
serotonin receptor agonist
antimigraine agent
|
|
gptkbp:contraindication
|
stroke
ischemic heart disease
uncontrolled hypertension
|
|
gptkbp:developedBy
|
GlaxoSmithKline
|
|
gptkbp:discoveredBy
|
gptkb:Glaxo
|
|
gptkbp:eliminationHalfLife
|
2 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstSynthesized
|
1980s
|
|
gptkbp:hasMolecularFormula
|
C14H21N3O2S
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Sumatriptan
|
|
gptkbp:KEGGID
|
D00454
|
|
gptkbp:legalStatus
|
prescription only
off-patent
|
|
gptkbp:mechanismOfAction
|
5-HT1B/1D receptor agonist
|
|
gptkbp:meltingPoint
|
121-124°C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:proteinBinding
|
14-21%
|
|
gptkbp:PubChem_CID
|
5358
5167
CHEMBL105
DB00669
|
|
gptkbp:routeOfAdministration
|
oral
subcutaneous injection
nasal
|
|
gptkbp:sideEffect
|
dizziness
tingling
drowsiness
flushing
chest discomfort
|
|
gptkbp:solubility
|
soluble in water
|
|
gptkbp:synonym
|
GR 43175
|
|
gptkbp:UNII
|
1T8B5M729Q
|
|
gptkbp:usedFor
|
migraine
cluster headache
|
|
gptkbp:bfsParent
|
gptkb:Triptans
|
|
gptkbp:bfsLayer
|
7
|